Allura xper fd20

A standard invasive coronary angiographic examination was performed on an Allura Xper FD20 catheterization system (Philips, Amsterdam, The Netherlands) within 2 weeks of the CMRA examination. An experienced cardiologist evaluated the presence of CCAs.

Intervention data including the use of combination therapy, duration of treatment (time from symptom onset to femoral artery accession), duration of intervention (time from femoral artery access to recanalization), devices used in each case (ACE 64 or ACE 68), and complications postintervention were obtained.
All procedures were performed under a DSA monoplane (Philips Allura Xper FD20). Procedures were performed with an 8F guide catheter with or without an intermediate catheter. For aspiration, ACE 64 or ACE 68 reperfusion catheters were advanced to the blood clot with the help of a microcatheter (Rebar 2.7F) and microguidewire (Transcend 0.014”). When an intracranial stent was required, antiplatelet therapy is used in the acute phase. If an intracranial stent was placed and there was no hemorrhagic complication on the study imaging, patients were started on dual antiplatelet therapy with aspirin 81 mg/day and clopidogrel 75 mg/day for 3 months and aspirin 81 mg/day for life.

MT was performed either using a BP angiography machine (Philips AlluraXper FD 20/20; Philips, The Netherlands) or an SP machine (Philips AlluraXper FD 20; Philips, The Netherlands). Angiosuites were regularly calibrated and controlled according to national and international standards.

This prospective, single-institution, two-arm study was conducted in compliance with the Health Insurance Portability and Accountability Act and was approved by the institutional review board. In January and February 2014, 26 consecutive patients with primary or secondary liver cancer treated with TACE at our institution using the C-arm system (Allura Xper FD20, Philips Healthcare, Best, the Netherlands) available at that time were included (control group). The imaging platform was then upgraded to the new platform (AlluraClarity) and a second cohort of 52 consecutive patients between March and June 2014 with liver cancer treated with TACE (study group) was included. Thus the final population included a total of 78 patients.

The procedures were performed in an angiography room with an Allura Xper FD20 instrument (Philips Medical Systems, Amsterdam, the Netherlands). All patients underwent ultrasonography-guided percutaneous femoral access with local anesthesia.
A pig-tail catheter (Super Torque MB, Cordis, Tipperary, Ireland), placed above the abdominal aneurysm, was used for digital subtraction angiography to identify aneurysm morphology. If the AAA extended into the iliac artery, internal iliac artery embolization was performed using an Interlock coil (Boston Scientific, Tipperary, Ireland) or an Amplatzer vascular plug (AGA Medical, Golden Valley, MN, USA). The main body and contralateral limb were deployed at a suitable place, and angiography was conducted to detect an endoleak or stent migration. The final angiography confirmed successful exclusion of an aneurysm, femoral access was removed, and Perclose Proglide was applied (Abbott, Green Oaks, IL, USA). When bleeding was absent, additional manual compression with gel pad compression was applied for 15 minutes and absolute bed rest was instructed for 8 hours.